POETIC: Trial of perioperative endocrine therapy – individualising care

Primary aim: To determine whether two weeks perioperative aromatase inhibitor (AI) therapy before and after surgery improves outcome compared with standard adjuvant therapy. Eligibility: Postmenopausal women with ER/PgR positive invasive breast cancer. Trial design: Phase III, multicentre, randomised trial Target accrual: 4350 patients Patients will be allocated in a 2:1 ratio to PERIOPERATIVE THERAPY with an AI for 4 weeks (two weeks before and two weeks after surgery) or NO PERIOPERATIVE THERAPY. Group I: PERIOPERATIVE THERAPY with an AI Choice of AI is according to centre policy and may be either anastrozole (1mg/day) or letrozole (2.5mg/day) Group II: NO PERIOPERATIVE THERAPY 4 weeks (two weeks before and two weeks after surgery)

Networks

  • ICR Clinical Trials & Statistics Unit (ICR-CTSU)

Contact Information

Email:
poetic-icrctsu@icr.ac.uk
Address:

ICR-CTSU
The Institute of Cancer Research
15 Cotswold Road
Sutton
Surrey
SM2 5NG
UK

Annual Statistics

Year Access Requests Received Access Requests Approved
Internal External Commercial Internal External Commercial
2015 N/A N/A N/A N/A N/A N/A
2016 N/A N/A N/A N/A N/A N/A
2017 N/A N/A N/A N/A N/A N/A
2018 N/A N/A N/A N/A N/A N/A
2019 N/A N/A N/A N/A N/A N/A